



British Hypertension Society

Annual Scientific Meeting

Monday 12th - Wednesday 14th
September 2011

Queens' College
Cambridge, UK

Final Programme



British Hypertension Society

Executive Committee

President:	Professor Mark Caulfield (London)
Vice-President:	Professor Tony Heagerty (Manchester)
Secretary:	Dr. Adrian Brady (Glasgow)
Treasurer:	Dr. Ian Wilkinson (Cambridge)
Ordinary Members:	Professor Francesco Cappuccio (Coventry) Dr. Neil Chapman (London) Professor Stephen Jackson (London) Dr. Terry McCormack (Whitby)

Working Party Chairs

BP Measurement WP:	Professor Richard McManus (Birmingham)
Collaborative Research WP:	Professor Morris Brown (Cambridge)
Educational Programmes WP:	Dr. James McLay (Aberdeen)
Information Service & Guidelines WP:	Professor Bryan Williams (Leicester)
Nurses WP:	Mrs. Naomi Stetson (London)

Administration

Administrative Officer:

Mrs. Jackie Howarth
BHS Administrative Officer
c/o Hypertension Research Team, Clinical Sciences Wing,
Glenfield Hospital, Leicester, LE3 9QP
Tel: +44 (0)7717 467973
Email: bhs@le.ac.uk
Web: www.bhsoc.org

Meetings Secretariat:

Hampton Medical Conferences Ltd.,
113-119 High Street, Hampton Hill, Middlesex, TW12 1NJ
Tel: +44 (0)20 8979 8300 (switchboard)
Fax: +44 (0)20 8979 6700
Email: hmc@hamptonmedical.com
Web: www.hamptonmedical.com

Major Sponsors and Supporters

The British Hypertension Society would like to express its gratitude to the following companies for their financial support:

Major Sponsors:



Daiichi Sankyo UK Ltd.



Takeda UK Ltd.

Supporter:

The British Hypertension Society gratefully acknowledges the support of the British Heart Foundation



Welcome

Dear Colleague,

We are pleased to invite you to attend the 30th Annual Scientific Meeting of the British Hypertension Society, which will be held from **Monday 12th to Wednesday 14th September 2011** in **Queens' College, Cambridge, UK**.



For the first time in its 30 year history, the Society is delighted to open the doors to its Annual Scientific Meeting to both members and non-members and, in particular, we hope to welcome overseas visitors representing other national hypertension and cardiovascular societies. Other changes which have been made this year to the format include the introduction of day delegate rates and separate fees for registration and accommodation to allow more flexibility in attendance.

In a second new feature we will commence on Monday afternoon with BHS *Live!* on the 2011 NICE Hypertension Guidelines, which will have been launched just prior to this year's BHS annual congress. The Chairman of the NICE Hypertension Guideline Development Group, Professor Bryan Williams, together with some of the Group's other members, will present the new hypertension guidelines and then invite the audience to participate in an active, frank and lively discussion about their content, delivery and implementation. The programme then will move into oral presentations of the highest quality research, being considered for the Young Investigators' Awards.

The full congress programme includes presentations by invited speakers on a broad range of topics including sleep and cardiovascular disease, blood pressure variability, cardiovascular imaging in the hypertensive patient, further new research presentations and posters, plus presentations of new research and topical discussion from the Nurses' Working Party. We are particularly pleased that one of our founding members and past-Presidents, Professor Peter Sever, will be giving this year's Sir George Pickering Lecture. There will be discussion of interesting and unusual clinical cases, as well as presentations of the latest data emerging from clinical trials during 2011. We are also looking forward to an entertaining post-dinner debate between Anna Dominiczak and Neil Poulter, refereed by Ian Wilkinson!

This year to recognise the 30 years of international contribution of this Society to hypertension research and patient care we will be inaugurating the British Hypertension Society Anniversary Award Lecture as an award for outstanding scientific contribution to hypertension research. The inaugural Anniversary Award Lecturer for 2011 is Professor Murray Esler from the Baker Institute in Melbourne for his work on the sympathetic nervous system and renal denervation.

The meeting has been made possible by major sponsors Daiichi Sankyo UK Ltd and Takeda UK Ltd and our exhibitors, to whom we extend our deepest thanks.



Professor Mark Caulfield
President



Dr. Adrian Brady
Secretary

On behalf of the British Hypertension Society Executive Committee



Venue:

Queens' College

Cambridge, CB3 9ET.

Tel: 01223 335511 (main College number)
01223 335590 (Registration Desk during the conference)

Fax: 01223 335971 (for incoming faxes during the conference)

Website: www.queens.cam.ac.uk

Oral Presentations:

British Hypertension Society lectures will take place in the Fitzpatrick Hall. Nurses Working Party lectures on Tuesday 13th September will take place in the Bowett Room.

Poster Presentations:

Posters will be displayed for the whole meeting. Presenters will be available for discussion during the chaired Poster Discussion Session from 10.30 – 11.30 hrs on Wednesday 14th September.

Young Investigators' Prizes:

Orals:

BHS Young Investigator's Oral Prizes

Abstracts shortlisted for these prizes will be given in Session 2 (16.30 – 18.00 hrs on Monday 12th September) and Session 3 (09.00 – 10.30 hrs on Tuesday 13th September). The winners will be announced at the Conference Dinner on Tuesday 13th September.

Posters:

The BHS Jack Ledingham Young Investigator's Poster Prize

Abstracts eligible for this prize (indicated with an asterisk in the Programme) will be presented in the Poster Discussion Session at 10.30 hrs on Wednesday 14th September. The winner will be announced at the end of the meeting.

Internet Access:

Wireless internet access is available in the Angevin Room, Conservatory and Bar. Computers will be available for delegates' use in the Angevin Room.



Programme Overview

	Monday 12 th September 2011	Tuesday 13 th September 2011		Wednesday 14 th September 2011
09.00		Session 3A BHS	Session 3B Nurses WP	Session 7 Clinical Session
09.30		<i>Coffee and Exhibition</i>		<i>Coffee and Poster Discussion Session</i>
10.00		Session 4A BHS	Session 4B Nurses WP	
10.30		<i>Coffee and Exhibition</i>		
11.00	<i>Registration, Coffee and Exhibition</i>	Sir George Pickering Lecture		Session 8 Latest News from Clinical Trials
11.30		<i>Lunch</i>		
12.00		<i>Lunch</i>		
12.30	<i>Lunch</i>	<i>Lunch</i>		<i>Close of Meeting and Lunch</i>
13.00	<i>Lunch</i>			
13.30	<i>Lunch</i>			
14.00	Session 1 NICE Hypertension Guidelines	Session 5A BHS	Session 5B Nurses WP	
14.30		<i>Tea and Exhibition</i>		
15.00		<i>Tea and Exhibition</i>		
15.30		<i>Tea and Exhibition</i>		
16.00	<i>Tea and Exhibition</i>	<i>Tea and Exhibition</i>		
16.30	Session 2 Submitted Abstracts	Session 6A BHS	Session 6B Nurses WP	
17.00		<i>Annual Business Meeting</i>		
17.30		<i>Annual Business Meeting</i>		
18.00		<i>Annual Business Meeting</i>		
18.30		<i>Annual Business Meeting</i>		
19.00		<i>Annual Business Meeting</i>		
19.30	<i>Dinner</i>	<i>Conference Reception, Dinner and Awards</i>		
20.00	<i>Dinner</i>			
20.30	<i>Debate</i>			
21.00	<i>Debate</i>			
21.30	<i>Debate</i>	<i>Debate</i>		

PROGRAMME: Monday 12th September 2011

<i>11.00 – 12.30</i>	<i>Arrival of delegates and Registration</i>	<i>Registration Foyer</i>
<i>12.30 – 14.00</i>	<i>Lunch</i>	<i>Dining Hall</i>
14.00 – 16.00	SESSION 1: NICE Hypertension Guidelines	<i>Fitzpatrick Hall</i>
	Chair: M.J. Caulfield (London)	
	1.1 NICE/BHS guidelines – the scope and process Professor Bryan Williams Chair, 2011 NICE Hypertension Guideline Development Group	
	1.2 Evidence to Recommendations <i>(Summaries by members of the Guideline Development Group)</i>	
	<ul style="list-style-type: none"> • Measurement and monitoring • Treatment of hypertension • Cost of hypertension treatment • Implementation • Evidence gaps & new research 	<p>R. McManus B. Williams M. Caulfield T. McCormack, N. Stetson, M. Watts M. Caulfield</p>
<i>16.00 – 16.30</i>	<i>Tea</i>	

16.30 – 18.00**SESSION 2: Submitted Abstracts***Fitzpatrick Hall*

(Young Investigator's Prize)

Chair: A.M. Heagerty (Manchester)

- 16.30 - 16.40 2.1 PPAiRGC1 β is a genetic determinant of the cardiovascular risk factor, Thromboxane A2 – an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) sub-study
N. McCarthy, C. Vangjeli, P. Surendran, A. Treumann, C. Rooney, E. Ho, P. Sever, S. Thom, A. Hughes, P. Munroe, P. Howard, T. Johnson, M.J. Caulfield, D. Shields, E. O'Brien, D. Fitzgerald, A. Stanton (Dublin, London)
- 16.40 - 16.45 Discussion
- 16.45 - 16.55 2.2 The influence of the brain on the control of mean arterial pressure in normal and hypertensive young adults
J.M. Coulson, K. Murphy, A.D. Harris, M. Fjodorova, J.R. Cockcroft, R.G. Wise (Cardiff)
- 16.55 - 17.00 Discussion
- 17.00 - 17.10 2.3 Mechanistic insights into the relationship between wave reflection and retinal artery flow pulsatility
B.J. McDonnell, J. Coulson, M. Zagura, M. Munnery, E.J. Stohr, R. Shave, C.M. McEniery, I.B. Wilkinson, J.R. Cockcroft (Cardiff, Tartu, Cambridge)
- 17.10 - 17.15 Discussion
- 17.15 - 17.25 2.4 Cross-sectional and longitudinal 10 year follow-up of central pulse pressure components and its reversal by vasodilating therapy in women
M. Cecelja, B. Jiang, T. Spector, P. Chowienczyk (London)
- 17.25 - 17.30 Discussion
- 17.30 - 17.40 2.5 Dietary nitrate fails to lower blood pressure in patients with type 2 diabetes
M. Gilchrist, P.G. Winyard, A.C. Shore, N. Benjamin (Exeter)
- 17.40 - 17.45 Discussion
- 17.45 - 17.55 2.6 Maternal hemodynamics at 11-13 weeks of gestation and the risk of pre-eclampsia
A. Khalil, R. Akolekar, A. Syngelaki, M. Elkhouley, K. Nicoalides (London)
- 17.55 - 18.00 Discussion
- 19.30 – 20.30 Dinner, Dining Hall

20.30 – 21.30**Post-Dinner Debate***Dining Hall*

Title: **This house believes that experimental models have been of little use in hypertension research**

Chair: **Dr. Ian Wilkinson** (Cambridge)

For: **Professor Neil Poulter** (London)

Against: **Professor Anna Dominiczak** (Glasgow)

PROGRAMME: Tuesday 13th September 2011

09.00 – 10.30

Parallel Sessions

SESSION 3A BHS Session - Submitted Abstracts (Young Investigator's Prize)	<i>Fitzpatrick Hall</i>	SESSION 3B Nurses Working Party Session Abstracts and Case Studies	<i>Bowett Room</i>
---	-------------------------	---	--------------------

Session 3A

BHS Submitted Abstracts

Fitzpatrick Hall

(Young Investigator's Prize)

Chair: I.B. Wilkinson (Cambridge)

- 09.00 – 09.10 3A.1 Half of an unselected series of aldosterone-producing adenomas have somatic mutation of the KCNJ5 channel and a zona fasciculata profile
E.A.B. Azizan, B. Lam, G. Hoffman, R. Kuc, S. Newhouse, M.J. Brown (Cambridge)
- 09.10 – 09.15 Discussion
- 09.15 – 09.25 3A.2 Is GPR61, an orphan G Protein-Coupled Receptor (GPCR), a candidate regulator of aldosterone secretion?
L. Haris Shaikh, E.A.B. Azizan, J. Zhou, R. Kuc, A. Davenport, M.J. Brown (Cambridge)
- 09.25 – 09.30 Discussion
- 09.30 – 09.40 3A.3 Comparisons of spot v 24h urine samples for population estimates of salt intake
C. Ji, M.A. Miller, F.P. Cappuccio (Coventry)
- 09.40 – 09.45 Discussion
- 09.45 – 09.55 3A.4 Hypertension in Tanzanian elderly: the disparity between prevalence, detection and treatment – a rule of sixths?
M.J. Dewhurst, F. Dewhurst, W.K. Gray, G. Orega, P. Chaote, R.W. Walker (Newcastle upon Tyne, Moshi, Boman'gombe)
- 09.55 – 10.00 Discussion
- 10.00 – 10.10 3A.5 The effect of life course systolic blood pressure on interventricular wall thickness
A.K. Ghosh, R. Hardy, D. Kuh, A.D. Hughes (London)
- 10.10 – 10.15 Discussion
- 10.15 – 10.25 3A.6 Endogenous hydrogen sulfide (H₂S) and novel slow release H₂S donors protect human endothelial cells from oxidative stress-induced cell death
S. Le Trionnaire, **J.L. Whatmore**, A. Perry, M.E. Wood, M. Whiteman (Exeter)
- 10.25 – 10.30 Discussion

Session 3B

Nurses Working Party Session

Bowett Room

Chair: N. Stetson (London)

- 09.00 – 09.10 3B.1 Nurse led hypertension clinics: evolving ahead of the evidence?
C.E. Clark, L.F.P. Smith, G. Harding, R.S. Taylor, J.L. Campbell (Exeter, West Coker)
- 09.10 – 09.15 Discussion
- 09.15 – 09.25 3B.2 Nurse specialist role in optimising treatment in resistant hypertension
J. Bunker, **W. Callister**, P. Sever (London)
- 09.25 – 09.30 Discussion

09.30 – 09.40	3B.3	To compare the efficiency of blood pressure reduction with or without the chemical profile P. Rabasse (Stockport, Manchester)
09.40 – 09.45		Discussion
09.45 – 09.55	3B.4	Plasma renin activity in the South Asian population – an intermediate group S. Patel , I. Uddin, A. Ward, F.L. Ng, I. Uddin, M.J. Caulfield, M.D. Lobo (London)
09.55 – 10.00		Discussion
10.00 – 10.10	3B.5	Salt intake in hypertensive patients with at or above-target blood pressures S. Patel, I. Uddin , A. Ward, F.L. Ng, M.J. Caulfield, M.D. Lobo (London)
10.10 – 10.15		Discussion
10.15 – 10.25	3B.6	Impact of telemetry enabled home blood pressure monitoring: Experiences of patients and professionals participating in the HITS randomised controlled trial of telemetry enabled home blood pressure (BP) monitoring J. Hanley , J. Ure, B. McKinstry, P. Padfield, S. Wilde, C. Pagliari (Edinburgh)
10.25 – 10.30		Discussion
10.30 – 11.00		<i>Coffee</i>
11.00 – 11.45		Parallel Sessions

SESSION 4A BHS Session - Submitted Abstracts	<i>Fitzpatrick Hall</i>	SESSION 4B Nurses Working Party Session	<i>Bowett Room</i>
---	-------------------------	--	--------------------

Session 4A **BHS Submitted Abstracts** *Fitzpatrick Hall*
Chair: A.J.B. Brady (Glasgow)

11.00 – 11.10	4A.1	Ethnic differences in aortic pulse wave velocity occur in the descending aorta independent of blood pressure and may be related to vitamin D M.R. Rezai , S.G. Anderson, N. Sattar, J. Finn, F. Wu, J.K. Cruickshank (Manchester, Glasgow)
11.10 – 11.15		Discussion
11.15 – 11.25	4A.2	Systolic inter-arm blood pressure difference is associated with increased cardiovascular and all-cause mortality in hypertension: meta-analysis C.E. Clark , R.S. Taylor, A.C. Shore, J.L. Campbell (Exeter)
11.25 – 11.30		Discussion
11.30 – 11.40	4A.3	Winner of the High BP Research Council of Australia Early Career Oral Presentation: Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism, but not in patients with essential hypertension E. Pimenta (Woolloongabba, Australia)
11.40 – 11.45		Discussion

Session 4B **Nurses Working Party Session** *Bowett Room*
Chair: A. Nixon (Brechin)

11.00 - 11.30	4B.1	Hypertension in the elderly T. McCormack (London)
11.30 – 11.45		Discussion

11.50 - 12.50

SIR GEORGE PICKERING LECTURE

Chair: M.J. Caulfield

**Treatment of hypertension in the 21st Century
Professor Peter Sever (London)**

Professor Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-Director of the International Centre for Circulatory Health and Head of the Disease Prevention Section of the National Heart and Lung Institute, Imperial College London; Theme Leader for Cardiovascular Disease of the Biomedical Research Centre, Imperial College Healthcare NHS Trust and, in 2009, was appointed as a Senior Investigator of the National Institute for Health Research.

After graduating from the University of Cambridge, Professor Sever completed his training at St Mary's Hospital Medical School in London. He became an Honorary Consultant Physician and Senior Lecturer in Medicine at St Mary's Hospital in 1976. In 1980, he was appointed Professor of Clinical Pharmacology and Therapeutics at St Mary's Hospital Medical School, which was subsequently incorporated into the Imperial College School of Medicine.

Professor Sever is Joint Editor-in-Chief of the *Journal of the Renin-Angiotensin-Aldosterone System*. Professor Sever is a past President of the British Hypertension Society and the European Council for Blood Pressure and Cardiovascular Research and past Chairman of the Fellowships Committee of the British Heart Foundation. He is also a Fellow of the European Society of Cardiology. In 2010, he was presented with the AstraZeneca Award from the International Society for Hypertension for his contribution to the clinical pharmacology and therapy of arterial hypertension.

Professor Sever's research interests include the pathophysiology of vascular disease, the evaluation of antihypertensive drug therapy and the impact of multiple risk factor intervention for the prevention of cardiovascular disease.



13.00 – 14.15

Lunch, Dining Hall

14.15 – 15.45

Parallel Sessions

SESSION 5A	<i>Fitzpatrick Hall</i>	SESSION 5B	<i>Bowett Room</i>
BHS Session – Submitted Abstracts		Nurses Working Party Session	

Session 5A**BHS Submitted Abstracts***Fitzpatrick Hall***Chair: F.P. Cappuccio (Coventry)**

- 14.15 - 14.25 5A.1 Cardiovascular outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up
A.K. Gupta, C.L. Chang, B. Dahlof, N.R. Poulter, P.S. Sever (London, Gothenburg)
- 14.25 – 14.30 Discussion
- 14.30 – 14.40 5A.2 Acute effects of dietary nitrate on glucose handling
S. Lidder, J. Hunt, S. Omar, A. Webb (London)
- 14.40 – 14.45 Discussion
- 14.45 – 14.55 5A.3 Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes
C. Delles, U. Neisius, G. Bilo, K. Stolarz-Skrzypek, J.A. Staessen, J. Redon, E. Agabiti Rosei, O. Melander, F. Zannad, S. Laurent, A. Zanchetti, A.F. Dominiczak, InGenious HyperCare Investigators (Glasgow, Milan, Krakow, Leuven, Pamplona, Brescia, Malmö, Nancy, Paris)

- 14.55 – 15.00 Discussion
- 15.00 – 15.10 5A.4 Sixteen novel loci influence blood pressure and cardiovascular risk
G. Ehret, P.B. Munroe, K. Rice, M. Bochud, A. Johnson, D. Chasman, A. Vernon-Smith, B. Psaty, G. Abecasis, A. Charavarti, P. Elliott, C. van Diujn, C. Newton Cheh, D. Levy, **M. Caulfield**, T. Johnson (Geneva, London, Seattle, Lausanne, Bethesda, Boston, Reykjavik, Michigan, Baltimore)
- 15.10 – 15.15 Discussion
- 15.15 – 15.25 5A.5 The impact of malaria in pregnancy on changes in blood pressure in children over the first year of life
O.O. Ayoola, O.O. Omotade, I. Gemmell, P.E. Clayton, J.K. Cruickshank (Manchester, Ibadan)
- 15.25 – 15.30 Discussion
- 15.30 – 15.40 5A.6 Both amiloride and nebivolol have a more favourable effect on glucose tolerance than hydrochlorothiazide in the treatment of essential hypertension - results of a double blind, placebo controlled, randomised cross over study
A.J. Stears, S.H. Woods, M.M. Watts, J. Graggaber, T.J. Burton, M.J. Brown (Cambridge)
- 15.40 – 15.45 Discussion

Session 5B Nurses Working Party Session

Bowett Room

Chair: J. Bunker (London)

- 14.15 - 14.40 5B.1 Bariatric surgery
A. Miras (London)
- 14.40 - 14.50 Discussion
- 14.50 - 15.30 5B.2 'Thinking Yourself Free' – an introduction to applied cognitive behaviour therapy for stress management and client motivation
D. Edwards (Manchester)
- 15.30 - 15.45 Discussion
- 15.45 – 16.15 *Tea*

16.15 – 17.25 Parallel Sessions

SESSION 6A <i>Fitzpatrick Hall</i>	SESSION 6B <i>Bowett Room</i>
BHS Session - Invited Speakers	Nurses Working Party Session

Session 6A

BHS Invited Speakers

Fitzpatrick Hall

Chair: N. Chapman (London)

- 16.15 - 16.40 6A.1 Sleep and CVD
F.P. Cappuccio (Coventry)
- 16.40 - 16.50 Discussion
- 16.50 - 17.15 6A.2 Blood pressure variability
P. Rothwell (Oxford)
- 17.15 - 17.25 Discussion

Session 6B**Nurses Working Party Session***Bowett Room***Chair: A. deVries (Aberdeen)**16.15 - 16.40 6B.1 Arthritis and CVD risk
T. MacDonald (Dundee)

16.40 - 16.50 Discussion

16.50 - 17.15 6B.2 How to write an abstract
S. Brett (London)

17.15 - 17.25 Discussion

17.25 - 18.15 **Annual Business Meeting** (BHS Members only)*Fitzpatrick Hall*

19.30 Drinks Reception

Exhibition Area

20.00 Conference Dinner and Awards

*Dining Hall***PROGRAMME: Wednesday 14th September 2011**

09.00 - 10.30

SESSION 7: Clinical Session*Fitzpatrick Hall***Chair: T. McCormack (Whitby)****Clinical Cases:**09.00 - 09.10 7.1 Complex labile hypertension – a life on hold
F. Ng (London)09.10 - 09.15 Commentary
M. Lobo (London)09.15 - 09.25 7.2 Renal denervation in resistant hypertension, with target organ damage
J. Davies (London)09.25 - 09.30 Commentary
N. Chapman (London)09.30 - 09.40 7.3 A year in Hypertension research
A. Brady (Glasgow)

09.40 - 09.45 Discussion

09.40 - 09.55 7.4 Hypertension in the very elderly (HYVET): latest data
S. Jackson (London)

09.55 - 10.00 Discussion

10.00 - 10.20 7.5 Cardiovascular imaging in the hypertensive patient
S. Petersen (London)

10.20 - 10.30 Discussion

10.30 - 11.30 **Coffee and Poster Discussion Session****Poster Group**

PA	Clinical Trials and Studies I
PB	BP Measurement and Haemodynamics
PC	Cardiovascular Physiology and Pharmacology
PD	Basic Science/ Haemodynamics II
PE	Endocrine and Metabolic Studies/ Clinical Trials and Studies II

Chair

G. McInnes
T. MacDonald
TBA
TBA
N. Poulter

11.30 – 13.00		SESSION 8: Latest News from Clinical Trials	<i>Fitzpatrick Hall</i>
		Chair: S.H.D Jackson (London)	
11.30 – 11.45	8.1	PATHWAY and new BHS Research Programmes M. Brown (Cambridge)	
11.45 – 11.50		Discussion	
11.50 - 12.05	8.2	Lowering blood pressure in acute stroke P. Bath (Nottingham)	
12.05 - 12.10		Discussion	
12.10 - 12.25	8.3	Is telemetry the future for hypertension management in primary care? B. McKinstry (Edinburgh)	
12.25 - 12.30		Discussion	

12.30 - 12.55 8.4 **THE BHS ANNIVERSARY PRIZE LECTURE** **Chair: M.J. Caulfield**

The sympathetic nervous system through the ages: From Thomas Willis to radiofrequency ablation of the renal sympathetic nerves in hypertension

Professor Murray Esler (Melbourne, Australia)

Professor Murray Esler is a cardiologist and medical scientist, based at the Baker IDI Heart and Diabetes Institute and the Alfred Hospital, Melbourne, Australia. His research interests are: The human sympathetic nervous system; Stress, and its effects on the heart and blood pressure; Causes and treatment of high blood pressure and heart failure; Neurotransmitters of the human brain.

He is the author of more than 350 papers on these topics. Professor Esler's principal research contribution has been the development of isotope dilution methodology to study the human sympathetic nervous system in internal organs not accessible to microneurography ("regional noradrenaline spillover" technique), and the application of this tool in the investigation of the sympathetic neural physiology of circulatory control, ageing, exercise and mental stress responses, and the neural pathophysiology of cardiac failure and essential hypertension. His demonstration of a high level of chronic activation of the cardiac sympathetic outflow in patients with heart failure provided the theoretical backdrop for the evaluation of beta-adrenergic blockers in this condition. More recently, his demonstration of activation of the renal sympathetic outflow in essential hypertension was the stimulus for the development of a new treatment for difficult to control patients, radio-frequency ablation of the renal sympathetic nerves with purpose-designed renal artery catheter. He was the chief investigator of a study demonstrating the successful application of this new treatment in patients with severe, drug-resistant hypertension (Lancet 2010;376:1903-1910).



12.55 – 13.05 Discussion

13.05 **Award: The BHS Jack Ledingham Young Investigator's Poster Prize**

Close of Meeting and Lunch

Poster Presentations

*Posters marked with an asterisk are eligible to be considered for The Jack Ledingham Young Investigator's Poster Prize

Posters PA Clinical Trials and Studies I Chair: G. McInnes

- PA.1 A case of failed renal denervation – can autonomic function tests be used to predict response to treatment?
PO Julu, M Matson, I Renfrew, MD Lobo (London, United Kingdom)
- PA.2* Promoting understanding about hypertension and cardiovascular disease amongst ethnic minorities in London
I Ahmed, N Ahmed, MS Amin, S Latif, F Ahmed, A Stephenson (London, United Kingdom)
- PA.3* Antihypertensive medications may contribute to syncopal episodes in hypertensive subjects with left ventricular hypertrophy
SI Balendra, S Singh, S Chaudhri, AM Salmasi (Cambridge, United Kingdom; London, United Kingdom)
- PA.4* Long-term effects of 3-month telemetric blood pressure intervention in inadequately treated patients with arterial hypertension
CL Neumann, EM Rieken, JM Schmidt Thrun, N Fischer, EG Schulz (Göttingen, Germany)
- PA.5 Subclinical organ damage – microalbuminuria, a marker of coronary heart disease
RA Sascau, C Statescu, D Baltag, L Anghel, CM Arsenescu Georgescu (Iasi, Romania)
- PA.6* Determinants of salt intake in the UK: results using spatial analysis
C Ji, N-B Kandala, FP Cappuccio (Coventry, United Kingdom)
- PA.7 Alkaline phosphatase and arterial structure and function in hypertensive African men: the SABPA study
R Schutte, HWH Huisman, L Malan, JM van Rooyen, W Smith, MCP Glynn, CMC Mels, CMT Fourie, NT Malan, AE Schutte (Potchefstroom, South Africa)

Posters PB BP Measurement and Haemodynamics I Chair: T. MacDonald

- PB.1 Blood pressure control for a 2-year cohort in the Hypertension in the Very Elderly Trial (HYVET)
C Bulpitt, N Beckett, R Peters, A Fletcher (London, United Kingdom)
- PB.2 Impact of haemostatic factors and ethnicity on mortality independent of blood pressure and aortic stiffness
SG Anderson, AH Heald, JK Cruickshank (Manchester, United Kingdom)
- PB.3 How is blood pressure variability defined?
K Taylor, D Nunan, E Adams, R Stevens, R Perera, A Ward, C Heneghan (Oxford, United Kingdom)
- PB.4 Peripheral arterial tonometry (PAT) technology to assess endothelial function in pregnancy
C Delles, DM Carty, LA Anderson, C Nicolson Duncan, DP Baird, L Rooney, AF Dominiczak (Glasgow, United Kingdom)
- PB.5* Prevalence of low and abnormal Ankle-Brachial Index and their association with traditional risk factors in a multi-ethnic adult general practice population
JC Ingoe, AJ Scally, K Kain (Leeds, United Kingdom)
- PB.6 Increased central blood pressure in black young adults is associated with elevated peripheral vascular resistance, but reduced large artery stiffness: The ENIGMA Study
CM McEniery, A Garrett, N Baber, JR Cockcroft, IB Wilkinson (Cambridge, United Kingdom)

Posters PC Cardiovascular Physiology and Pharmacology Chair: TBA

- PC.1* Left atrial function assessed with doppler echocardiography rather than left atrial volume predicts recurrence in patients with paroxysmal atrial fibrillation
JH Yoon, CW Koh, WB Pyun, SK Rheu, SJ Rim (Seoul, Republic of Korea)
- PC.2 Effect of exercise-induced hypertension on cardiac markers in ultra-marathon (100km) runners
CW Goh, SJ Lim, SK Ryu, WB Pyun, YS Byun (Seoul, Republic of Korea)
- PC.3 Impact of antihypertensive therapy on LV systolic dyssynchrony in patients with never-treated and uncomplicated hypertension
BJ Kwon, KY Choi, DB Kim, SW Jang, EJ Cho, SH Ihm, JH Kim (Seoul, Republic of Korea)

- PC.4 Improvements in P-wave dispersion between different combination therapy of antihypertensives
JY Han, SI Ha, DH Choi, YY Koh, KS Chang, SP Hong, JW Chung (Gwang-ju, Republic of Korea)
- PC.5* Routine angioplasty after fibrinolytic therapy for ST-segment elevation myocardial infarction: an updated meta-analysis (RAFT-STEMI)
JDA Magno, JD Alcover, ADC Javier, FER Punzalan (Manila, Philippines)
- PC.7* Unclaimed Electrocardiogram Reports at the Inpatient Charity Areas of a tertiary hospital (The ERICA Study)
JDA Magno, MO Matulac, EB Reyes (Manila, Philippines)
- PC.8* Permanent pacemaker implantation as a complication following isolated aortic valve surgery – a 1 year retrospective review at a tertiary cardiothoracic centre
H Dhutia, J Makan (London, United Kingdom)

Posters PD

Basic Science/Haemodynamics II

Chair: TBA

- PD.1* Candidate genes for blood pressure regulation identified on rat chromosome 3 using congenic strategy
HHC Koh-Tan, JD McClure, MW McBride, D Graham, AF Dominiczak (Glasgow, United Kingdom)
- PD.2* A large genome-wide association study of pulse pressure and mean arterial pressure reveals seven novel blood pressure loci
LV Wain, GC Verwoert, PF O'Reilly, G Shi, T Johnson, PB Munroe, BM Psaty, MJ Caulfield, DC Rao, MD Tobin, P Elliott, CM van Duijn (Leicester, United Kingdom; (ICBP-GWAS), United Kingdom)
- PD.3 Rap2 GTP binding protein mediate the antiproliferative effects of estrogen on human arteriolar smooth muscle cells: involvement of membrane estrogen receptors and cyclic AMP
AH Eid (Doha, Qatar)
- PD.4* The effects of regular aerobic exercise training on hypertensive rats' kidney: an unbiased stereological study
G Hamidian, V Dabidi Roshan (Tabriz, Islamic Republic of Iran)
- PD.5* Urotensin 2 signalling pathway and genetic regulation of blood pressure
R Debiec, M Denniff, TA Barnes, P Christofidou, LDS Bloomer, CP Nelson, E Zukowska-Szzechowska, FJ Charchar, DG Lambert, NJ Samani, M Tomaszewski (Leicester, United Kingdom)

Posters PE

Endocrine and Metabolic Studies/
Clinical Trials and Studies II

Chair: N. Poulter

- PE.1 The association between plasma vitamin C concentrations and blood pressure in 20,926 men and women: cross sectional evidence from the EPIC-Norfolk general population-based study
PK Myint, RN Luben, NJ Wareham, K-T Khaw (Norwich, United Kingdom; Cambridge, United Kingdom)
- PE.2 Endothelial cell FOS expression and pre-eclampsia
C Delles, RM Mackenzie, VC Sandrim, MW McBride, JD McClure, DM Carty, AF Dominiczak (Glasgow, United Kingdom)
- PE.3 Can ethnicity be an effect modifier for the association between systolic blood pressure and adiposity?
Y Sun, M Miller, F Cappuccio (Coventry, United Kingdom)
- PE.4 The role of blood pressure, plasma vitamin D and aldosterone on LV geometry in ageing British men
M-R Rezai, SG Anderson, S Balakrishnannair, B Cowan, A Young, N Sherratt, N Sattar, J Finn, F Wu, JK Cruickshank (Manchester, United Kingdom)
- PE.5 Sex differences in the association between plasma levels of the novel vasodilatory gas hydrogen sulfide, adiposity and micro- and macrovascular function in vivo
M Whiteman, WD Strain, K Gooding, C Ball, D Mawson, JE Tooke, AC Shore (Exeter, United Kingdom)
- PE.6* Nutritional deficiencies in subjects with known hypertension and diabetes in a multi-ethnic practice population
JC Ingoe, K Kain (Leeds, United Kingdom)
- PE.7 Investigation and management of primary aldosteronism – a review of 59 cases and audit of outcomes in a tertiary referral centre
G Currie, M Freel, J Connell, PJ O'Dwyer (Glasgow, United Kingdom)

Major Sponsors

Daiichi Sankyo UK Ltd.
Chiltern Place, Chalfont Park
Gerrards Cross, Bucks., SL9 0BG
www.takeda.co.uk



Daiichi-Sankyo The DAIICHI SANKYO GROUP is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly € 7.3 billion, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the DAIICHI SANKYO GROUP has created a "Hybrid

Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.

The company's world headquarters are in Tokyo. Its European base is located in Munich. DAIICHI SANKYO EUROPE has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit www.daiichisankyo.com or www.daiichisankyo.eu

Takeda UK Ltd.

Takeda House, Mercury Park, Wycombe Lane, Wooburn Green
High Wycombe, Bucks., HP10 0HH
www.takeda.co.uk



Takeda UK & Ireland is the UK and Ireland subsidiary of Japan's largest pharmaceutical company, a research based global enterprise with global net sales of \$13 billion (2008), employing more than 15,700 people in more than 90 countries.

Takeda UK & Ireland's current 2010/2011 portfolio of products addresses some of the largest areas of patient need, which are strategic priorities for the NHS: Type 2 diabetes; cardiovascular disease and cancer. Takeda UK & Ireland markets two important oral diabetes therapies, the UK's most widely prescribed ARB for the treatment of hypertension and heart failure and the world's most widely prescribed luteinizing hormone-releasing hormone analogue (LHRHa), which is used mainly for treating prostate cancer. Takeda's oncology portfolio also includes the first treatment approved for osteosarcoma in more than 20 years.

Equally important is the unique way in which Takeda UK interacts with its NHS partners. Having taken the revolutionary step in 2004 to replace its traditional salesforce of medical representatives with locally autonomous Regional Account Directors (RADs), the company is committed to developing innovative partnerships with healthcare providers within the NHS to support the advancement of patient care.

Exhibitors

A&D Instruments Ltd

24 Blacklands Business Park, Abingdon, Oxon, OX14 1DY

Website: www.aandd-eu.net

Fukuda Denshi UK Ltd

13 Westminster Court, Hipley Street, Old Woking, Surrey, GU22 0LG

Website: www.fukuda.co.uk

HealthSTATS Technologies (UK) Limited

93-95 Gloucester Place, London W1U 6JQ

Website: www.healthstats.com

Omron Healthcare Europe

Kruisweg 577, 2131 NA Hoofddorf, The Netherlands

Website: www.eu.omron.com

Rudolf Riester GmbH

PO Box 35, Brauckstraße 31, DE-72417 Jungingen

Website: www.riester.de

Unimedica Ltd

The Old Church, 89b Quicks Road, Wimbledon, London, SW19 1EX

Website: www.unimedica.co.uk



www.bhsoc.org

Secretariat:

Hampton Medical Conferences Ltd
113-119 High Street, Hampton Hill, Middlesex, TW12 1NJ

Tel: 020 8979 8300 | Fax: 020 8979 6700

Email: hmc@hamptonmedical.com

Web: www.hamptonmedical.com